The last 3 years have seen the emergence of promising targeted therapies for the treatment
of hepatocellular carcinoma (HCC). Sorafenib has been the mainstay of treatment for a …

Clinical and laboratory studies over recent decades have established branched evolution as
a feature of cancer. However, while grounded in somatic selection, several lines of evidence …

Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, typically
develops on the background of chronic liver disease and is an aggressive disease with …

The observation and analysis of intra-tumour heterogeneity (ITH), particularly in genomic
studies, has advanced our understanding of the evolutionary forces that shape cancer …

Cellular diversity in tumors is a key factor for therapeutic failures and lethal outcomes of solid
malignancies. Here, we determined the single-cell transcriptomic landscape of liver cancer …

Intratumor heterogeneity, which fosters tumor evolution, is a key challenge in cancer
medicine. Here, we review data and technologies that have revealed intra-tumor …

In multiple myeloma malignant plasma cells expand within the bone marrow. Since this site
is well-perfused, a rapid dissemination of “fitter” clones may be anticipated. However, an …

Aneuploidy is a hallmark of breast cancer; however, knowledge of how these complex
genomic rearrangements evolve during tumorigenesis is limited. In this study, we developed …

Objective Hepatocellular carcinoma (HCC) is heterogeneous, especially in multifocal
tumours, which decreases the efficacy of clinical treatments. Understanding tumour …

Intratumor heterogeneity has been widely reported in human cancers, but our knowledge of
how this genetic diversity emerges over time remains limited. A central challenge in studying …